Stellaromics has launched Pyxa, the first commercial platform delivering multiplexed 3D spatial transcriptomics in intact tissue up to 100 micrometres thick. The platform marks a shift from traditional 2D thin-section analysis to true 3D analysis preserving native tissue organisation. Pyxa is available through a limited Early Access Programme, following a beta programme at three institutions since late 2025, including University of Glasgow, UC Irvine, and Emory University. The platform captures subcellular detail for hundreds of molecular targets simultaneously, enabling researchers to resolve complex 3D tissue organisation and characterise cell-cell interactions across multiple layers. Spun out from Stanford University and MIT laboratories, Boston-based Stellaromics will formally debut the programme at the AGBT meeting in Orlando.

Stellaromics, a Boston-based spatial multi-omics company, has appointed Stacie Weninger and Steve McPhail to its board of directors as it scales its Pyxa spatial platform. Weninger, a venture partner at F-Prime with over 20 years' experience in neuroscience companies, brings expertise in bridging academic discovery and clinical application. McPhail offers three decades of executive leadership in genomics and diagnostics, having served as CEO of Expression Analysis for 15 years and most recently as chief commercial officer at Fluidigm. The appointments aim to support Stellaromics' expansion in the life sciences sector as it develops high-resolution 3D spatial multi-omics technology for researchers and drug developers worldwide.

Stellaromics has installed its Pyxa 3D spatial multi-omics system at Emory University School of Medicine, marking the third beta program site following deployments at the University of Glasgow and UC Irvine. The system will be used in Dr Hailing Shi's laboratory to research RNA regulation in the brain and neurodegenerative diseases. Dr Shi, assistant professor in Emory's Department of Human Genetics, will use Pyxa to study the spatial organisation of the central nervous system at cellular and subcellular resolution. The system delivers high-resolution, multiplexed 3D spatial transcriptomics in tissue sections up to 100 micrometres thick, capturing subcellular detail for hundreds of molecular targets simultaneously. Boston-based Stellaromics is advancing 3D spatial multi-omics technology to enable breakthroughs in human health research.